Daniel Barros de Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Barros de Castro has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Vanderson Souza Sampaio
Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil
9 shared publications - José Ueleres Braga
Fundação Oswaldo Cruz, Brasil
5 shared publications - Wuelton Marcelo Monteiro
Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil
4 shared publications - Antonio José Leal Costa
Universidade Federal do Rio de Janeiro, Brasil
3 shared publications - Bernardino Cláudio de Albuquerque
Fundacao de Vigilancia em Saude do Amazonas, Manaus, Brazil
3 shared publications - Fernando Val
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD) Clinical Research Unit Manaus, AM
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Elsevier in SSRN Electronic Journal
COVID-19 vaccine rollout, geographic inequalities and severe outcomes in the Brazilian Amazon: a population-based retrospective cohort study
Objectives: To evaluate geographic disparities and vaccination effects on readmission and mortality among patients hospitalized for severe COVID-19 in Amazonas, Brazil. Study Design: Retrospective cohort study. Methods: We linked surveillance (SIVEP-Gripe) and mortality (SIM) databases from January 2020 to December 2022, including all hospitalized patients with severe acute respiratory syndrome (SARS). Outcomes included time to severe COVID-19 readmission and death. Survival analyses and cure-fraction models assessed the effects of residence (capital vs. countryside) and vaccination period. Results: The cohort comprised 117,701 individuals. Incidence was consistently higher in the capital than in the countryside, peaking in 2021 (297.1 vs. 78.2 per 100,000). The post-vaccination period was associated with an approximately 83–84% reduction in the incidence of severe COVID-19 hospitalizations in both regions. Capital residents had a longer time to readmission, while countryside residents had a higher probability of cure. Survival probability was more than four times higher during the post-vaccination period. Conclusions: Vaccination has substantially reduced the incidence and improved survival, thereby mitigating pre-existing geographic disparities. Strengthening vaccination coverage and health system capacity remains essential to reduce regional inequalities.
- 26 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCOVID-19 vaccine rollout, geographic inequalities and severe outcomes in the Brazilian Amazon: a population-based retrospective cohort study
Objectives: To evaluate geographic disparities and vaccination effects on readmission and mortality among patients hospitalized for severe COVID-19 in Amazonas, Brazil. Study Design: Retrospective cohort study. Methods: We linked surveillance (SIVEP-Gripe) and mortality (SIM) databases from January 2020 to December 2022, including all hospitalized patients with severe acute respiratory syndrome (SARS). Outcomes included time to severe COVID-19 readmission and death. Survival analyses and cure-fraction models assessed the effects of residence (capital vs. countryside) and vaccination period. Results: The cohort comprised 117,701 individuals. Incidence was consistently higher in the capital than in the countryside, peaking in 2021 (297.1 vs. 78.2 per 100,000). The post-vaccination period was associated with an approximately 83–84% reduction in the incidence of severe COVID-19 hospitalizations in both regions. Capital residents had a longer time to readmission, while countryside residents had a higher probability of cure. Survival probability was more than four times higher during the post-vaccination period. Conclusions: Vaccination has substantially reduced the incidence and improved survival, thereby mitigating pre-existing geographic disparities. Strengthening vaccination coverage and health system capacity remains essential to reduce regional inequalities.
- Open Access
Diagnostic information from a negative QuantiFERON-TB Gold Plus result in adults evaluated for tuberculosis in Brazil and South Africa
Interferon-gamma release assays detect Mycobacterium tuberculosis infection but cannot distinguish infection from active tuberculosis (TB). We evaluated the diagnostic information provided by QuantiFERON-TB Gold Plus (QFT-Plus) among adults investigated for active TB in Brazil and South Africa. Adults with presumptive TB were prospectively enrolled by convenience sampling. QFT-Plus was the index test, and diagnostic classification required microbiological confirmation of TB or an established alternative diagnosis. QFT-Plus results did not inform diagnostic classification. Accuracy was assessed among participants with determinate results, primarily using likelihood ratios. Of 723 participants tested, 48 (6.6%) had indeterminate results, all due to low mitogen responses. Among 675 participants with determinate results, 147 (21.8%) had confirmed TB. Sensitivity was 68.0% (95% CI, 60.1–75.0), specificity was 59.3% (95% CI, 55.0–63.4), and the negative likelihood ratio was 0.54 (95% CI, 0.42– 0.69). At the observed prevalence, a negative result left a 13.1% probability of active TB. Negative likelihood ratio confidence intervals included 1 in both South African HIV strata. Specificity was higher among participants with HIV in both countries. Adding TB2 to TB1 alone identified 15 additional TB cases and generated 18 additional positive results among participants without active TB. HIV and active TB were independently associated with indeterminate results in exploratory regression. A negative QFT-Plus result provided insufficient information to exclude active TB. Higher negative predictive values among participants with HIV reflected lower disease prevalence and higher specificity rather than greater sensitivity. Negative or indeterminate results should not terminate diagnostic evaluation. IMPORTANCE: Blood tests that detect immune responses to Mycobacterium tuberculosis can yield negative results in people with active tuberculosis. Understanding how much reassurance a negative result provides is therefore important when these tests are encountered during diagnostic investigation. Among symptomatic adults in Brazil and South Africa, a negative QuantiFERON-TB Gold Plus result left a substantial probability of active disease. Differences between populations showed why apparently reassuring negative predictive values can be misleading. The additional antigen tube detected more cases but did not overcome the test’s limited ability to exclude disease. Indeterminate results were associated with human immunodeficiency virus infection and active tuberculosis. These findings support laboratory reporting and clinical interpretation that clearly communicate the limitations of negative and indeterminate results and the need for continued investigation when active tuberculosis remains suspected.
Open AccessDiagnostic information from a negative QuantiFERON-TB Gold Plus result in adults evaluated for tuberculosis in Brazil and South Africa
Interferon-gamma release assays detect Mycobacterium tuberculosis infection but cannot distinguish infection from active tuberculosis (TB). We evaluated the diagnostic information provided by QuantiFERON-TB Gold Plus (QFT-Plus) among adults investigated for active TB in Brazil and South Africa. Adults with presumptive TB were prospectively enrolled by convenience sampling. QFT-Plus was the index test, and diagnostic classification required microbiological confirmation of TB or an established alternative diagnosis. QFT-Plus results did not inform diagnostic classification. Accuracy was assessed among participants with determinate results, primarily using likelihood ratios. Of 723 participants tested, 48 (6.6%) had indeterminate results, all due to low mitogen responses. Among 675 participants with determinate results, 147 (21.8%) had confirmed TB. Sensitivity was 68.0% (95% CI, 60.1–75.0), specificity was 59.3% (95% CI, 55.0–63.4), and the negative likelihood ratio was 0.54 (95% CI, 0.42– 0.69). At the observed prevalence, a negative result left a 13.1% probability of active TB. Negative likelihood ratio confidence intervals included 1 in both South African HIV strata. Specificity was higher among participants with HIV in both countries. Adding TB2 to TB1 alone identified 15 additional TB cases and generated 18 additional positive results among participants without active TB. HIV and active TB were independently associated with indeterminate results in exploratory regression. A negative QFT-Plus result provided insufficient information to exclude active TB. Higher negative predictive values among participants with HIV reflected lower disease prevalence and higher specificity rather than greater sensitivity. Negative or indeterminate results should not terminate diagnostic evaluation. IMPORTANCE: Blood tests that detect immune responses to Mycobacterium tuberculosis can yield negative results in people with active tuberculosis. Understanding how much reassurance a negative result provides is therefore important when these tests are encountered during diagnostic investigation. Among symptomatic adults in Brazil and South Africa, a negative QuantiFERON-TB Gold Plus result left a substantial probability of active disease. Differences between populations showed why apparently reassuring negative predictive values can be misleading. The additional antigen tube detected more cases but did not overcome the test’s limited ability to exclude disease. Indeterminate results were associated with human immunodeficiency virus infection and active tuberculosis. These findings support laboratory reporting and clinical interpretation that clearly communicate the limitations of negative and indeterminate results and the need for continued investigation when active tuberculosis remains suspected.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59 (suppl 1)
Temporal and spatial trends in infectious disease mortality in Amazonas, Brazil, 2013-2024: implications for surveillance
Background: Infectious and parasitic diseases remain a significant cause of mortality in the state of Amazonas, and are shaped by structural, environmental, and social vulnerabilities. Methods: This descriptive, population-based study examines the temporal evolution and spatial distribution of mortality caused by infectious disease in Amazonas between 2013 and 2024. We analyzed monthly mortality rates using data from the Mortality Information System (SIM), focusing on International Classification of Diseases, 10th Revision (ICD-10) Chapter I (A00-B99) and selected codes from Chapter X (J09-J18). Results: Despite initial stability (2013-2018), mortality rates increased markedly from 2019 to 2021, associated with the direct and indirect impacts of the Coronavirus Disease (Covid-19) pandemic. After 2022, rates stabilized but remained elevated, indicating a shift toward a new endemic level. Spatial analysis revealed a persistent concentration of deaths in metropolitan areas and riverine municipalities, with recent expansion into medium-sized towns of the interior. Pneumonia, human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS), septicemia, and tuberculosis accounted for most deaths, with a predominance of older adults and people identified as mixed race or Indigenous. High proportions of ill-defined causes and non-specific diagnoses, particularly in pneumonia and sepsis, highlight diagnostic limitations and the urgent need to strengthen death investigation services and expand etiological investigation. Conclusions: Our findings highlight persistent inequalities in health access and call for integrated public health strategies, including improved surveillance systems, expanded diagnostic capacity, and intersectoral approaches adapted to the Amazonian context.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59 (suppl 1)
Open AccessTemporal and spatial trends in infectious disease mortality in Amazonas, Brazil, 2013-2024: implications for surveillance
Background: Infectious and parasitic diseases remain a significant cause of mortality in the state of Amazonas, and are shaped by structural, environmental, and social vulnerabilities. Methods: This descriptive, population-based study examines the temporal evolution and spatial distribution of mortality caused by infectious disease in Amazonas between 2013 and 2024. We analyzed monthly mortality rates using data from the Mortality Information System (SIM), focusing on International Classification of Diseases, 10th Revision (ICD-10) Chapter I (A00-B99) and selected codes from Chapter X (J09-J18). Results: Despite initial stability (2013-2018), mortality rates increased markedly from 2019 to 2021, associated with the direct and indirect impacts of the Coronavirus Disease (Covid-19) pandemic. After 2022, rates stabilized but remained elevated, indicating a shift toward a new endemic level. Spatial analysis revealed a persistent concentration of deaths in metropolitan areas and riverine municipalities, with recent expansion into medium-sized towns of the interior. Pneumonia, human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS), septicemia, and tuberculosis accounted for most deaths, with a predominance of older adults and people identified as mixed race or Indigenous. High proportions of ill-defined causes and non-specific diagnoses, particularly in pneumonia and sepsis, highlight diagnostic limitations and the urgent need to strengthen death investigation services and expand etiological investigation. Conclusions: Our findings highlight persistent inequalities in health access and call for integrated public health strategies, including improved surveillance systems, expanded diagnostic capacity, and intersectoral approaches adapted to the Amazonian context.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59 (suppl 1) , e0470
Climate change and tropical medicine in the Amazon: contributions from a research center, gaps and future priorities
The Amazon Basin is undergoing rapid climatic and environmental changes, with direct impacts on infectious disease transmission and public health. Rising temperatures, altered rainfall patterns, and more frequent extreme events are reshaping vector and pathogen dynamics. Additionally, deforestation and land-use change increase human and animal exposure. These combined factors intensify the risk of disease transmission in the region. This narrative review synthesizes evidence generated by researchers from a reference center in tropical medicine in the Amazon, integrating epidemiological analyses, experimental studies, ecological and predictive modelling, and health systems research conducted over the past decade. The evidence indicates that temperature and hydrological variability affect vector competence, pathogen development, and host-vector contact rates, producing nonlinear and context-dependent transmission outcomes. Extreme hydroclimatic events additionally disrupt healthcare delivery, hinder surveillance, and compromise continuity of care for infections requiring sustained treatment, such as tuberculosis and HIV. Emerging advances, including species distribution modelling, remote sensing, and integrated climate-epidemiological surveillance, provide predictive capacity to anticipate outbreaks and identify emerging hotspots. However, substantial research gaps persist, particularly regarding multi-stressor interactions, mechanistic pathways of climate-pathogen-vector adaptation, and health system resilience under climatic extremes. From the perspective of a reference center that integrates education, research, and healthcare delivery in tropical medicine, this article articulates a research agenda for climate-informed tropical medicine, highlighting priorities for interdisciplinary research, surveillance innovation, and adaptive public health strategies in the Amazon and other climate-sensitive regions.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 59 (suppl 1) , e0470
Open AccessClimate change and tropical medicine in the Amazon: contributions from a research center, gaps and future priorities
The Amazon Basin is undergoing rapid climatic and environmental changes, with direct impacts on infectious disease transmission and public health. Rising temperatures, altered rainfall patterns, and more frequent extreme events are reshaping vector and pathogen dynamics. Additionally, deforestation and land-use change increase human and animal exposure. These combined factors intensify the risk of disease transmission in the region. This narrative review synthesizes evidence generated by researchers from a reference center in tropical medicine in the Amazon, integrating epidemiological analyses, experimental studies, ecological and predictive modelling, and health systems research conducted over the past decade. The evidence indicates that temperature and hydrological variability affect vector competence, pathogen development, and host-vector contact rates, producing nonlinear and context-dependent transmission outcomes. Extreme hydroclimatic events additionally disrupt healthcare delivery, hinder surveillance, and compromise continuity of care for infections requiring sustained treatment, such as tuberculosis and HIV. Emerging advances, including species distribution modelling, remote sensing, and integrated climate-epidemiological surveillance, provide predictive capacity to anticipate outbreaks and identify emerging hotspots. However, substantial research gaps persist, particularly regarding multi-stressor interactions, mechanistic pathways of climate-pathogen-vector adaptation, and health system resilience under climatic extremes. From the perspective of a reference center that integrates education, research, and healthcare delivery in tropical medicine, this article articulates a research agenda for climate-informed tropical medicine, highlighting priorities for interdisciplinary research, surveillance innovation, and adaptive public health strategies in the Amazon and other climate-sensitive regions.
- Open Access
- 21 February 2025
- Published by Elsevier in World Neurosurgery: X
- Vol. 26
Traumatic brain injury in the Brazilian Amazon: A neglected disease
- 21 February 2025
- Published by Elsevier in World Neurosurgery: X
- Vol. 26
Open AccessTraumatic brain injury in the Brazilian Amazon: A neglected disease
- Open Access
- 1 September 2024
- Published by Instituto Evandro Chagas in Revista Pan-Amazônica de Saúde
- Vol. 15
Fatores de risco para óbitos por influenza A H1N1 no estado do Amazonas, no ano epidêmico de 2019
Palavras-chave: Vírus da Influenza A Subtipo H1N1; Síndrome Respiratória Aguda Grave; Monitoramento Epidemiológico; Vigilância em Saúde Pública; Amazônia
- 1 September 2024
- Published by Instituto Evandro Chagas in Revista Pan-Amazônica de Saúde
- Vol. 15
Open AccessFatores de risco para óbitos por influenza A H1N1 no estado do Amazonas, no ano epidêmico de 2019
Palavras-chave: Vírus da Influenza A Subtipo H1N1; Síndrome Respiratória Aguda Grave; Monitoramento Epidemiológico; Vigilância em Saúde Pública; Amazônia
- 19 May 2024
- Published by Elsevier in Acta Tropica
- Vol. 256, 107266
Spatio-temporal analysis of American Tegumentary Leishmaniasis incidences in the Brazilian state of Amazonas: 2011 to 2022
- 19 May 2024
- Published by Elsevier in Acta Tropica
- Vol. 256, 107266
Spatio-temporal analysis of American Tegumentary Leishmaniasis incidences in the Brazilian state of Amazonas: 2011 to 2022
- Open Access
- 1 July 2023
- Published by Oxford University Press (OUP) in Virus Evolution
- Vol. 9 (2) , vead059
Multiple introductions and country-wide spread of DENV-2 genotype II (Cosmopolitan) in Brazil
Dengue virus serotype 2, genotype Cosmopolitan (DENV-2-GII), is one of the most widespread DENV strains globally. In the USA, DENV-2 epidemics have been dominated by DENV-2 genotype Asian-American (DENV-2-GIII), and the first cases of DENV-2-GII were only described in 2019, in Peru, and in 2021 in Brazil. To gain new information about the circulation of DENV-2-GII in Brazil, we sequenced 237 DENV-2 confirmed cases sampled between March 2021 and March 2023 and revealed that DENV-2-GII is already present in all geographic regions of Brazil. The phylogeographic analysis inferred that DENV-2-GII was introduced at least four times in Brazil, between May 2020 and August 2022, generating multiple clades that spread throughout the country with different success. Despite multiple introductions of DENV-2-GII, analysis of the country-wide laboratory surveillance data showed that the Brazilian dengue epidemic in 2022 was dominated by DENV-1 in most states. We hypothesize that massive circulation of DENV-2-GIII in previous years in Brazil might have created a population immune barrier against symptomatic homotypic reinfections by DENV-2-GII, leading to sustained cryptic circulation in asymptomatic cases and localized outbreaks of this new genotype. In summary, our study stresses the importance of arboviral genomic surveillance to close monitoring and better understanding the potential impact of DENV-2-GII in the coming years.
- 1 July 2023
- Published by Oxford University Press (OUP) in Virus Evolution
- Vol. 9 (2) , vead059
Open AccessMultiple introductions and country-wide spread of DENV-2 genotype II (Cosmopolitan) in Brazil
Dengue virus serotype 2, genotype Cosmopolitan (DENV-2-GII), is one of the most widespread DENV strains globally. In the USA, DENV-2 epidemics have been dominated by DENV-2 genotype Asian-American (DENV-2-GIII), and the first cases of DENV-2-GII were only described in 2019, in Peru, and in 2021 in Brazil. To gain new information about the circulation of DENV-2-GII in Brazil, we sequenced 237 DENV-2 confirmed cases sampled between March 2021 and March 2023 and revealed that DENV-2-GII is already present in all geographic regions of Brazil. The phylogeographic analysis inferred that DENV-2-GII was introduced at least four times in Brazil, between May 2020 and August 2022, generating multiple clades that spread throughout the country with different success. Despite multiple introductions of DENV-2-GII, analysis of the country-wide laboratory surveillance data showed that the Brazilian dengue epidemic in 2022 was dominated by DENV-1 in most states. We hypothesize that massive circulation of DENV-2-GIII in previous years in Brazil might have created a population immune barrier against symptomatic homotypic reinfections by DENV-2-GII, leading to sustained cryptic circulation in asymptomatic cases and localized outbreaks of this new genotype. In summary, our study stresses the importance of arboviral genomic surveillance to close monitoring and better understanding the potential impact of DENV-2-GII in the coming years.
- 26 May 2023
- Published by Uniao Atlantica de Pesquisadores in Peer Review
- Vol. 5 (10) , 238-252
Análise espacial das taxas de incidência de hepatite C no Amazonas, Brasil, 2008-2018
Objetivo: analisar a distribuição espacial das taxas de incidência de hepatite C no estado do Amazonas, no período de 2008 a 2018. Método: estudo ecológico e transversal com dados provindos do Sistema de Informação de Agravos de Notificação concedidos pela Fundação de Vigilância em Saúde do estado do Amazonas. Foram feitos os cálculos das taxas de incidência bruta, empírica bayesiana, incidência suavizada, índice de Moran Global e Local. Resultados: foram notificados 3.275 casos, a maioria foram diagnosticados de forma laboratorial 3.251 (99,2%), forma crônica 2.800 (85,5%), sexo masculino 1.683 (51,4%), zona urbana 2.943 (89,9%), faixa etária 40-50 anos 1.608 (69,6%), pardos 2.696 (82,3%), ensino fundamental incompleto 464 (14,2%), provável fonte de infeção sexual 181 (5,5%) e baixo preenchimento dos campos essenciais. O índice de moran global deu positivo e significativo (p≤0,05) em todos os anos estudados. Conclusão: a hepatite C ainda é muito frequente no Amazonas e afeta mais jovens e adultos de baixa escolaridade. Sua incidência se distribuiu espacialmente de forma não aleatória e significativa, apresentando clusters espaciais de incidência preocupante entre os municípios de Manaus e seus arredores.
- 26 May 2023
- Published by Uniao Atlantica de Pesquisadores in Peer Review
- Vol. 5 (10) , 238-252
Análise espacial das taxas de incidência de hepatite C no Amazonas, Brasil, 2008-2018
Objetivo: analisar a distribuição espacial das taxas de incidência de hepatite C no estado do Amazonas, no período de 2008 a 2018. Método: estudo ecológico e transversal com dados provindos do Sistema de Informação de Agravos de Notificação concedidos pela Fundação de Vigilância em Saúde do estado do Amazonas. Foram feitos os cálculos das taxas de incidência bruta, empírica bayesiana, incidência suavizada, índice de Moran Global e Local. Resultados: foram notificados 3.275 casos, a maioria foram diagnosticados de forma laboratorial 3.251 (99,2%), forma crônica 2.800 (85,5%), sexo masculino 1.683 (51,4%), zona urbana 2.943 (89,9%), faixa etária 40-50 anos 1.608 (69,6%), pardos 2.696 (82,3%), ensino fundamental incompleto 464 (14,2%), provável fonte de infeção sexual 181 (5,5%) e baixo preenchimento dos campos essenciais. O índice de moran global deu positivo e significativo (p≤0,05) em todos os anos estudados. Conclusão: a hepatite C ainda é muito frequente no Amazonas e afeta mais jovens e adultos de baixa escolaridade. Sua incidência se distribuiu espacialmente de forma não aleatória e significativa, apresentando clusters espaciais de incidência preocupante entre os municípios de Manaus e seus arredores.
- Open Access
Tucuxi-BLAST: Enabling fast and accurate record linkage of large-scale health-related administrative databases through a DNA-encoded approach
Background: Public health research frequently requires the integration of information from different data sources. However, errors in the records and the high computational costs involved make linking large administrative databases using record linkage (RL) methodologies a major challenge. Methods: We present Tucuxi-BLAST, a versatile tool for probabilistic RL that utilizes a DNA-encoded approach to encrypt, analyze and link massive administrative databases. Tucuxi-BLAST encodes the identification records into DNA. BLASTn algorithm is then used to align the sequences between databases. We tested and benchmarked on a simulated database containing records for 300 million individuals and also on four large administrative databases containing real data on Brazilian patients. Results: Our method was able to overcome misspellings and typographical errors in administrative databases. In processing the RL of the largest simulated dataset (200k records), the state-of-the-art method took 5 days and 7 h to perform the RL, while Tucuxi-BLAST only took 23 h. When compared with five existing RL tools applied to a gold-standard dataset from real health-related databases, Tucuxi-BLAST had the highest accuracy and speed. By repurposing genomic tools, Tucuxi-BLAST can improve data-driven medical research and provide a fast and accurate way to link individual information across several administrative databases.
Open AccessTucuxi-BLAST: Enabling fast and accurate record linkage of large-scale health-related administrative databases through a DNA-encoded approach
Background: Public health research frequently requires the integration of information from different data sources. However, errors in the records and the high computational costs involved make linking large administrative databases using record linkage (RL) methodologies a major challenge. Methods: We present Tucuxi-BLAST, a versatile tool for probabilistic RL that utilizes a DNA-encoded approach to encrypt, analyze and link massive administrative databases. Tucuxi-BLAST encodes the identification records into DNA. BLASTn algorithm is then used to align the sequences between databases. We tested and benchmarked on a simulated database containing records for 300 million individuals and also on four large administrative databases containing real data on Brazilian patients. Results: Our method was able to overcome misspellings and typographical errors in administrative databases. In processing the RL of the largest simulated dataset (200k records), the state-of-the-art method took 5 days and 7 h to perform the RL, while Tucuxi-BLAST only took 23 h. When compared with five existing RL tools applied to a gold-standard dataset from real health-related databases, Tucuxi-BLAST had the highest accuracy and speed. By repurposing genomic tools, Tucuxi-BLAST can improve data-driven medical research and provide a fast and accurate way to link individual information across several administrative databases.